Eli Lilly Bulls Take Charge Ahead Of Q4 — Can It Reach $1000?

Core Viewpoint - Eli Lilly is set to report its fourth-quarter earnings, with Wall Street expecting an EPS of $4.94 and revenues of$13.66 billion, indicating strong market anticipation for the company's performance [1]. Stock Performance - Eli Lilly stock has shown a significant increase of 19.23% over the past year and 8.22% year-to-date [1]. - The current share price is $841.78, which is above the five-day, 20-day, and 50-day exponential moving averages, indicating strong bullish momentum [2]. - The stock has also crossed its 200-day simple moving average of$841.52, breaking resistance levels and signaling long-term bullish momentum [3]. Technical Indicators - The Moving Average Convergence Divergence (MACD) indicator is at 12.09, supporting a bullish outlook, while the Relative Strength Index (RSI) is at 64.87, suggesting the stock is nearing overbought territory but still has potential for further gains [3]. Analyst Ratings - The consensus analyst rating for Eli Lilly stock is a Buy, with a price target of $955.21, indicating a potential upside of 26.97$842.30 [5].